In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories

Leading The Dawn Chorus

Spearheading discussions with NICE, bluebird bio’s UK general manager Nicola Redfern has been central to efforts to introduce fresh reimbursement models within the health technology assessment process and commercial framework. Success could change the way cell and gene therapies are assessed and affect the outlook for many patients living with rare diseases.

Market Access Gene Therapy

China Makes Its Mark On R&D Pipeline And Novel Launches

The largest-ever rise in the number of active R&D companies, particularly in China, helped propel an unprecedented increase in the size of the biopharma pipeline in 2019. Meanwhile, the number of new active substances launched in their first market last year dropped as 2018’s superlative performance gave way to something more usual.

Clinical Trials Approvals Innovation

A Message For Medtechs: Adapt For the Future While You Can

With the World Health Organization pressing for an inquiry into the coronavirus pandemic, it is clear that lessons must be learned for how future global public health emergencies must be handled. Medical technology has played a key role in halting the speed of the pandemic, but why has it taken an episode like COVID-19 for medtech’s true value to be recognized? ZS principal Brian Chapman says things must never go back to where they were.

Business Strategies Commercial Digital Health

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development


Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More
Data Spotlight

Making Progress Against Rare Diseases

Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.

Accessing CAR-T Therapies

Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.

Infographic: 20 Years Of Mega-Deals

The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019. 

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Coronavirus-Driven Regulatory Changes Put Telehealth On The Map

Adoption of telehealth services has skyrocketed during the coronavirus outbreak and US experts are expecting the trend to continue post-pandemic, fundamentally transforming health care.

Coronavirus COVID-19 Digital Health

Is Cardiometabolic Ripe For A Revival?

Opportunities in the cardiometabolic field are increasing, following a period of limited investment from larger biopharma players. Still, challenges remain, such as accessing funding at the earlier stages of development. 

Commercial Business Strategies

Narasimhan's Culture Club On Song At Novartis

Taking over at the Swiss firm as CEO in 2018, Vas Narasimhan set about creating an "inspired, curious and unbossed organization." Two years on, he has put the spotlight on several initiatives that are up and running on a number of fronts to achieve that goal.

Commercial Companies

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Stick To The Plan – But Be Ready To Change

Know your strengths, surround yourself with experts and ensure your solution “does what it says on the tin.” These are among the guiding principles of Christophe Bancel, co-founder of France’s biopolymer innovator TISSIUM, a health care start-up on the cusp of commercialization.

Business Strategies C-Suite Speaks

Is CAR-NK The Natural Successor To CAR-Ts?

There is significant commercial potential on offer for the leading CAR-NK developers. While companies committed to continued CAR-T development will need to adapt and innovate in order to remain relevant, especially considering this disruptive new drug class.

Clinical Trials Innovation

What Does AI Excellence Look Like In Big Pharma?

Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.

C-Suite Speaks Digital Health

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Execs On The Move, May 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Companies

Titans Of Pharma 2020: 15 Leading CEOs Bag $266m In Compensation

See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.

Business Strategies Commercial

Finding Tomorrow’s Biopharma And Medtech CEOs

What are the skills future life sciences leaders will need in order to rise to the top of biopharma and medtech companies? A recent BioTrinity industry panel debated the profile of tomorrow’s leaders.

Business Strategies Commercial

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Leading The Dawn Chorus

Spearheading discussions with NICE, bluebird bio’s UK general manager Nicola Redfern has been central to efforts to introduce fresh reimbursement models within the health technology assessment process and commercial framework. Success could change the way cell and gene therapies are assessed and affect the outlook for many patients living with rare diseases.

Market Access Gene Therapy

Why Are Pharma Companies Still Spending $7bn A Year On DTC Advertising In US?

In the next evolution of health care, the pharmaceutical industry needs to preserve its customers, not the direct to customer advertising campaigns.

Business Strategies Commercial

Focusing On The Bigger Picture At The EMA

Tony Humphreys of the European Medicines Agency explains the thinking behind the agency’s regulatory science strategy, why the PRIME scheme is to get a boost, and why the need to tackle health threats ranked so low in a stakeholder consultation.

Europe Market Access

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals Shaping The Medical Industry, April 2020

This month’s column covers deals announced between 1-23 April 2020. 

Commercial Companies

Biopharma Quarterly Dealmaking Statistics, Q1 2020

During Q1, biopharmas brought in an aggregate $13.8bn in financing. M&A value reached $6.9bn, the majority from Gilead Sciences $4.9bn purchase of immuno-oncology firm Forty Seven. Alliances fetched $35bn in potential deal value, dominated by many Big Pharma tie-ups led by a $4bn discovery and development collaboration between AstraZeneca and Silence Therapeutics for siRNA therapeutics.

Deals Market Intelligence

What Next For Medtech And Investors Post-Coronavirus?

If a post-COVID-19 economic recovery starts properly in September, as some have suggested, how swift would a return to normal be for medtech and life sciences businesses? It depends what the new normal looks like, suggests life sciences legal firm Goodwin. But in the regulatory arena, agencies are working hard to keep market access a priority during the ongoing public health emergency.

Business Strategies Commercial
UsernamePublicRestriction

Register